CVR number 10068460
Industry 46.4610 Wholesale of pharmaceutical goods

BIOLIT ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/5
2020
2021/5
2021
2022/5
2022
2023/5
2023
2024/5
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  5.4% 5.4% 6.3% 3.8% 5.2%  
Credit score (0-100)  43 41 36 50 42  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/5
2020
2021/5
2021
2022/5
2022
2023/5
2023
2024/5
Net sales  0 0 0 0 0  
Gross profit  1,530 1,829 2,383 974 60.2  
EBITDA  1,530 1,829 2,383 974 60.2  
EBIT  1,530 1,829 2,383 974 60.2  
Pre-tax profit (PTP)  2,226.6 2,009.7 4,056.5 6,138.4 16,719.2  
Net earnings  1,736.7 1,567.6 3,164.1 4,788.0 13,041.0  
Pre-tax profit without non-rec. items  2,227 2,010 4,056 6,138 16,719  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/5
2020
2021/5
2021
2022/5
2022
2023/5
2023
2024/5
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  8,819 10,386 13,550 18,338 31,379  
Interest-bearing liabilities  3,747 4,680 5,583 6,957 8,790  
Balance sheet total (assets)  14,881 17,322 22,047 28,747 46,027  
Net Debt  -8,437 -10,261 -14,718 -21,002 -36,388  
 
See the entire balance sheet

Volume 
2019
2020/5
2020
2021/5
2021
2022/5
2022
2023/5
2023
2024/5
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,530 1,829 2,383 974 60.2  
Gross profit growth  -22.2% 19.6% 30.3% -59.1% -93.8%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  14,881 17,322 22,047 28,747 46,027  
Balance sheet change%  25.6% 16.4% 27.3% 30.4% 60.1%  
Added value  1,529.7 1,829.2 2,382.7 973.7 60.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2020/5
2020
2021/5
2021
2022/5
2022
2023/5
2023
2024/5
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  17.7% 13.6% 21.7% 25.2% 45.3%  
ROI %  21.0% 15.9% 24.9% 28.8% 51.7%  
ROE %  21.8% 16.3% 26.4% 30.0% 52.5%  

Solidity 
2019
2020/5
2020
2021/5
2021
2022/5
2022
2023/5
2023
2024/5
Equity ratio %  59.3% 60.0% 61.5% 63.8% 68.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -551.5% -561.0% -617.7% -2,157.0% -60,440.6%  
Gearing %  42.5% 45.1% 41.2% 37.9% 28.0%  
Net interest  0 0 0 0 0  
Financing costs %  4.2% 4.4% 4.1% 4.0% 2.7%  

Liquidity 
2019
2020/5
2020
2021/5
2021
2022/5
2022
2023/5
2023
2024/5
Quick Ratio  2.3 2.4 2.5 2.7 3.1  
Current Ratio  2.5 2.5 2.6 2.8 3.1  
Cash and cash equivalent  12,183.9 14,941.6 20,300.6 27,959.2 45,177.9  

Capital use efficiency 
2019
2020/5
2020
2021/5
2021
2022/5
2022
2023/5
2023
2024/5
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  6,109.5 7,397.3 8,782.9 -6,452.6 -9,811.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/5
2020
2021/5
2021
2022/5
2022
2023/5
2023
2024/5
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0